Boosting endocannabinoids reduced anxiety and depression from meth withdrawal in mice
The endocannabinoid-boosting compound URB597 prevented anxiety and depression behaviors in mice undergoing methamphetamine withdrawal, acting through CB1, CB2, and vanilloid receptor pathways.
Quick Facts
What This Study Found
Methamphetamine (30 mg/kg) caused anxiety and depression behaviors 3 days after withdrawal. URB597 (an endocannabinoid-enhancing compound) at 5-10 ng prevented these emotional deficits. The effect was blocked by CB1 antagonist AM251 and CB2 antagonist AM630, confirming involvement of both cannabinoid receptors. TRPV1 antagonist capsazepine showed dose-dependent effects: low doses blocked and high doses potentiated URB597's antidepressant action.
Key Numbers
Methamphetamine 30 mg/kg induced symptoms at 3 days; URB597 effective at 5-10 ng/mouse; CB1 antagonist AM251 (1 ug) blocked antidepressant effect; CB2 antagonist AM630 (5-10 ug) suppressed antidepressant activity; capsazepine showed dose-dependent bidirectional effects
How They Did This
Male NMRI mice received methamphetamine (30 mg/kg) and were tested 3 days later in elevated plus maze (anxiety) and forced swim test (depression). URB597 was administered intracerebroventricularly 10 minutes before testing. Receptor involvement was probed using specific antagonists for CB1, CB2, and TRPV1.
Why This Research Matters
Methamphetamine withdrawal causes severe anxiety and depression that drive relapse. Identifying the endocannabinoid system as a treatment target could provide new pharmacological approaches for managing stimulant withdrawal symptoms.
The Bigger Picture
The involvement of multiple receptor types (CB1, CB2, TRPV1) in mediating the anti-withdrawal effects suggests the endocannabinoid system offers multiple therapeutic entry points for treating stimulant withdrawal, rather than a single target.
What This Study Doesn't Tell Us
Male mice only. Intracerebroventricular administration is not a clinically practical delivery route. Forced swim and elevated plus maze are simplified models of human depression and anxiety. Three-day withdrawal window may not capture the full timeline of human methamphetamine withdrawal.
Questions This Raises
- ?Would systemically administered endocannabinoid modulators show similar effects?
- ?Do these findings extend to female subjects and to other stimulant withdrawal (cocaine, amphetamine)?
Trust & Context
- Key Stat:
- URB597 prevented both anxiety and depression in meth-withdrawn mice
- Evidence Grade:
- Mechanistic animal study with systematic receptor probing, but limited by male-only design and non-translatable drug delivery route.
- Study Age:
- Published in 2021.
- Original Title:
- URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels.
- Published In:
- Journal of psychopharmacology (Oxford, England), 35(7), 875-884 (2021)
- Database ID:
- RTHC-03112
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is URB597?
URB597 is a compound that blocks the enzyme FAAH, which breaks down the endocannabinoid anandamide. By preventing anandamide breakdown, URB597 effectively boosts the body's natural endocannabinoid signaling.
How is this relevant to cannabis?
URB597 enhances the same endocannabinoid system that cannabis acts on, but through the body's own compounds rather than external cannabinoids. This approach may offer therapeutic benefits without the psychoactive effects or abuse potential of cannabis itself.
Read More on RethinkTHC
- anxiety-leaving-house-weed-withdrawal-agoraphobia
- anxiety-response-technique-weed-withdrawal
- anxiety-toolkit-weed-withdrawal
- anxiety-worse-after-quitting-weed
- breathing-exercises-weed-withdrawal-anxiety
- cannabis-induced-anxiety
- does-weed-help-anxiety
- grounding-techniques-weed-withdrawal
- health-anxiety-weed-withdrawal
- manage-anxiety-without-weed
- quitting-weed-anxiety-disorder
- quitting-weed-anxiety-medication-ssri
- self-medicating-anxiety-with-weed
- therapy-quitting-weed-anxiety
- weed-and-anxiety
- weed-biphasic-effect-anxiety
- weed-generalized-anxiety-disorder
- weed-panic-attacks
- weed-paranoia
- weed-social-anxiety
- weed-tolerance-anxiety-stopped-working
- weed-withdrawal-anxiety
- weed-withdrawal-panic-attacks-night
- weed-withdrawal-work-anxiety
- withdrawal-anxiety-vs-real-anxiety
Cite This Study
https://rethinkthc.com/research/RTHC-03112APA
Ebrahimi-Ghiri, Mohaddeseh; Khakpai, Fatemeh; Zarrindast, Mohammad-Reza. (2021). URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels.. Journal of psychopharmacology (Oxford, England), 35(7), 875-884. https://doi.org/10.1177/0269881120965934
MLA
Ebrahimi-Ghiri, Mohaddeseh, et al. "URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels.." Journal of psychopharmacology (Oxford, 2021. https://doi.org/10.1177/0269881120965934
RethinkTHC
RethinkTHC Research Database. "URB597 abrogates anxiogenic and depressive behaviors in the ..." RTHC-03112. Retrieved from https://rethinkthc.com/research/ebrahimi-ghiri-2021-urb597-abrogates-anxiogenic-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.